Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.
AbstractBACKGROUND: Melanoma is the major cause of skin cancer death worldwide. Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes. Importantly, epidemiological studies have reported co-occurrence of melanoma and Parkinson's disease, suggesting that these two diseases could share common genetic components. METHODOLOGY/PRINCIPAL FINDINGS: Recently, we found that human melanoma cell lines highly express alpha-synuclein, whereas the protein is undetectable in the non-melanoma cancer cell lines tested. To investigate the expression of alpha-synuclein in human melanoma tissues, we immunostained sections of melanoma, nevus, non-melanocytic cutaneous carcinoma, and normal skin. alpha-Synuclein was positively detected in 86% of the primary and 85% of the metastatic melanoma sections, as well as in 89% of nevus sections. However, alpha-synuclein was undetectable in non-melanocytic cutaneous carcinoma and normal skin. CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi. Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
CitationPLoS One. 2010 May 5; 5(5):e10481
- Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
- Authors: Mehregan DR, Hamzavi I
- Issue date: 2000 Jun
- Role of Ser129 phosphorylation of α-synuclein in melanoma cells.
- Authors: Lee BR, Matsuo Y, Cashikar AG, Kamitani T
- Issue date: 2013 Jan 15
- Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
- Authors: Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL
- Issue date: 2008 Sep
- Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
- Authors: Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M
- Issue date: 1989 Sep 15
- Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
- Authors: de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN
- Issue date: 1997 Aug 1